It has been shown previously that our experimental agent, an isoquinoline derivative PARP-inhibitor, L-2286 (Fig. 1) had a beneficial effect against oxidative cell damage, against ischemia-reperfusion injury and the development of postinfarction or long-term high blood pressure-induced heart failure. Here, PARP1 is linked to heart failure.